What do systematic reviews say?

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.87 [0.83, 0.92]
  27 studies · 39180 participants
  High

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Taxane‐containing chemotherapy leads to lower disease‐free progression compared with any chemotherapy without taxane (high certainty).

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.88 [0.85, 0.92]
  29 studies · 41909 participants
  High

Taxane‐containing chemotherapy vs any chemotherapy without taxane

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 7 participants
  Low

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  OR 1.43 [0.89, 2.31]
  23 studies · 34154 participants
  Moderate

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Taxane‐containing chemotherapy probably leads to higher neuropathy (including grade 3/4 sensory or motor neuropathy, or both) compared with any chemotherapy without taxane (moderate certainty).

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  OR 6.89 [3.23, 14.71]
  22 studies · 31033 participants
  Moderate

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Taxane‐containing chemotherapy showed no clear difference in cardiotoxicity (including grade 3/4 and congestive cardiac failure) compared with any chemotherapy without taxane (moderate certainty).

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  OR 0.87 [0.56, 1.33]
  23 studies · 32894 participants
  Moderate

Chemotherapy vs chemotherapy alone

Chemotherapy showed no clear difference in overall survival (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  HR 1.05 [0.72, 1.54]
  2 studies · 121 participants
  Low

Chemotherapy vs chemotherapy alone

Chemotherapy showed no clear difference in progression‐free survival (taxane‐containing doublet therapy vs… compared with chemotherapy (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  HR 0.75 [0.52, 1.09]
  2 studies · 121 participants
  Low

Chemotherapy vs chemotherapy alone

It is very uncertain whether chemotherapy changes tumour response rate (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (very low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 1.47 [0.56, 3.89]
  2 studies · 121 participants
  Very low